JNJ-88998377

N/A

Report date: 2025/02/27 11:08:37
NME

Base Information

Drug NameJNJ-88998377
Drug Alias NameJNJ-88998377JNJ88998377
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVanilloid receptor antagonists
TargetsTransient receptor potential cation channel subfamily V member 1
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanPolandTurkey +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJohnson & Johnson (China) Investment Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A